Immunotherapy drug cemiplimab takes on aggressive breast cancer in new trial
NCT ID NCT04243616
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-positive or triple-negative breast cancer that expresses PD-L1. The main goal is to see how many achieve a pathological complete response—meaning no cancer remains in the breast or lymph nodes after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cemiplimab (Libtayo) plus chemotherapy (paclitaxel, carboplatin, doxorubicin, cyclophosphamide)
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for aggressive breast cancers, potentially improving long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The added immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States